Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody

被引：0

作者：

Ohsugi, Yoshiyuki ^{[1
]}

Kishimoto, Tadamitsu ^{[2
]}

机构：

[1] Chugai Pharmaceut Co Ltd, Tokyo 1038324, Japan

[2] Osaka Univ, Grad Sch Frontier Biosci, Lab Immunoregulat, Osaka, Japan

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷

关键词：

ACR response; anemia of chronic inflammation; fatigue; humanized anti-IL-6 receptor antibody; interleukin-6; rheumatoid arthritis; tocilizumab;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Evidence has accumulated indicating that proinflammatory cytokines play critical roles in the pathogenesis of RA. Recent clinical studies demonstrate that blockade of IL-6 signaling with tocilizumab, a recombinant humanized anti-interleukin-6 receptor antibody, is a new therapeutic option for the treatment of patients with RA refractory to conventional DMARD therapy and anti-TNF-alpha therapy. This paper discusses possible mechanisms of action, reviews the results of clinical trials, and discusses the place of tocilizumab in RA treatment.

引用

页码：1677 / 1691

页数：15

共 50 条

[1] Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Mihara, Masahiko
Ohsugi, Yoshiyuki
Kishimoto, Tadamitsu
[J]. OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2011, 3 : 19 - 29
[2] Successful Treatment of Reactive Arthritis With a Humanized Anti-Interleukin-6 Receptor Antibody, Tocilizumab
Tanaka, Toshio
Kuwahara, Yusuke
Shima, Yoshihito
Hirano, Toru
Kawai, Mari
Ogawa, Masako
Arimitsu, Junsuke
Hagihara, Keisuke
Narazaki, Masashi
Ogata, Atsushi
Kawase, Ichiro
Kishimoto, Tadamitsu
[J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (12): : 1762 - 1764
[3] Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
Koike, Ryuji
Harigai, Masayoshi
Atsumi, Tatsuya
Amano, Koichi
Kawai, Shinichi
Saito, Kazuyoshi
Saito, Tomoyuki
Yamamura, Masahiro
Matsubara, Tsukasa
Miyasaka, Nobuyuki
[J]. MODERN RHEUMATOLOGY, 2009, 19 (04) : 351 - 357
[4] Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders
Tanaka, Toshio
Hagihara, Keisuke
Shima, Yoshihito
Narazaki, Masashi
Ogata, Atsushi
Kumanogoh, Atsushi
[J]. DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 717 - 732
[5] Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
Sugimoto, K
Nishimoto, N
Kishimoto, T
Yoshizaki, K
Nishimura, T
[J]. ANNALS OF NUCLEAR MEDICINE, 2005, 19 (04) : 261 - 266
[6] Humanized anti-interleukin-6 receptor antibody
Larry Moreland
[J]. Current Rheumatology Reports, 2005, 7 (5) : 381 - 381
[7] Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
Kanji Sugimoto
Norihiro Nishimoto
Tadamitsu Kishimoto
Kazuyuki Yoshizaki
Tsunehiko Nishimura
[J]. Annals of Nuclear Medicine, 2005, 19 : 261 - 266
[8] Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis
Hirabayashi, Yasuhiko
[J]. MODERN RHEUMATOLOGY, 2021, 31 (01) : 70 - 79
[9] Intracellular Dynamics and Fate of a Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody, Tocilizumab
Fujimoto, Keiko
Ida, Hiroaki
Hirota, Yuko
Ishigai, Masaki
Amano, Jun
Tanaka, Yoshitaka
[J]. MOLECULAR PHARMACOLOGY, 2015, 88 (04) : 660 - 675
[10] Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
Kawashiri, Shin-ya
Kawakami, Atsushi
Yamasaki, Satoshi
Imazato, Takahiro
Iwamoto, Naoki
Fujikawa, Keita
Aramaki, Toshiyuki
Tamai, Mami
Nakamura, Hideki
Ida, Hiroaki
Origuchi, Tomoki
Ueki, Yukitaka
Eguchi, Katsumi
[J]. RHEUMATOLOGY INTERNATIONAL, 2011, 31 (04) : 451 - 456

← 1 2 3 4 5 →